Form D · Other Health Care
Confluence Life Sciences, Inc.
Saint Louis, MO · CIK 0001540502
Offering snapshot reported Apr 19, 2016 · SEC filing
- Reported sold
- $4.83M Offering amount: $5.44M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Apr 8, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 19, 2016 | Initial | $4,832,525 | No comparison | 16 | SEC filing |
| Jul 11, 2012 | Initial | $895,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-261658
Source: Form D, filed Apr 19, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Beardsley | Executive |
| Jennifer Bohnert | Executive |
| Charles Bolten | Director |
| Dan Broderick | Director |
| Daniel Janiak | Director |
| Michael Kuo | Director |
| Joseph Monahan | Director, Executive |
| Kyparissia Sirinakis | Director |
| Thomas Smart | Director |
| Walter Smith | Director, Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
4320 Forest Park Ave. Suite 303
Saint Louis, MO, 63108
Saint Louis, MO, 63108